Palbociclib improves survival in late endometrial cancer: study
Results from a phase 2 trial with letrozole in oestrogen receptor-positive patients presented at ESMO congress
AusDoc brings you the latest news from the European Society for Medical Oncology virtual congress 2020.
Palbociclib plus letrozole appears to prolong progression-free survival (PFS) in women with primary stage four or relapsed oestrogen receptor-positive endometrial cancer, Danish researchers say.
Results of the phase 2 study in 77 women were reported at the European Society for Medical Oncology (ESMO) virtual congress 2020.
Prior surgery, radiation therapy, chemotherapy or one line of endocrine therapy (medroxyprogesterone acetate or megestrol acetate) were permitted, Dr Mansoor Mirza of Rigshospitalet in Copenhagen told delegates.
